The global antibiotics market is expected to reach USD 36 billion in 2023 anticipated to grow at a CAGR of 1.2% during the forecast period 2023-2035.

Bacterial infections stand as a primary contributor to global mortality, accounting for one out of every eight deaths worldwide. This prevalence predominantly stems from the escalation of resistant pathogenic bacteria against conventional treatments. The Centers for Disease Control and Prevention (CDC) notes that managing infections from six multi-drug resistant bacteria incurs an annual cost of over USD 4.6 billion in the United States alone. Antibiotics, sourced from biological or chemical origins, play a critical role in preventing and treating various bacterial infections. Recent advancements have led to the approval of diverse broad-spectrum and narrow-spectrum antibiotics designed to combat a range of bacterial diseases such as anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis. Nevertheless, the development of antibiotic drugs encounters numerous challenges, including the emergence of multi-drug resistant bacteria, shortages?especially of penicillin and amoxicillin?and concerns regarding safety and efficacy. To address these challenges, stakeholders within the industry have actively engaged in research and development endeavors. Additionally, regulatory bodies such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the United States Food and Drug Administration (USFDA) have initiated campaigns to promote appropriate antibiotic usage and extend support to the industry. Through the collaborative efforts of industry and non-industry entities, accompanied by escalating concerns surrounding antimicrobial resistance, the global antibiotics market is anticipated to experience significant growth in the projected period.

Report Coverage
? The report examines the antibiotics market by categorizing it according to the type of drug class, target disease indication, type of therapy, route of administration and key geographical regions.
? It conducts an analysis of factors?such as drivers, restraints, opportunities, and challenges?that impact the market’s growth trajectory.
? The report evaluates the potential advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.
? Revenue forecasts for market segments are projected across four major regions.
? The executive summary segment provides an overview of the current global antibiotics market and its anticipated development in the medium to long term.
? It offers an introduction to antibiotics, detailing their characteristics, advantages, and classification based on chemical structure, mode of action, activity range, and source. This section encompasses historical perspectives, innovations, mechanisms of action, challenges, and future prospects.
? A comprehensive analysis covers approval years, regions, antibiotic types, mechanisms of action, spectrum of activity, target bacteria, disease indications, source nature, therapy types, administration routes, dosage forms, patient populations, and developer details.
? Similar to the generics analysis, a detailed examination focuses on branded antibiotics. Parameters considered include approval details, antibiotic types, mechanisms, spectrum, target bacteria, disease indications, therapy types, administration routes, dosage forms, patient populations, innovation types, and developer insights.
? An in-depth evaluation of clinical-stage antibiotics includes development statuses, antibiotic types, mechanisms, spectra, target bacteria, disease indications, therapeutic areas, therapy types, administration routes, dosage forms, patient populations, special designations, and developer analyses.
? Detailed profiles of significant players in antibiotic development encompass company overviews, key executives, financial data (if available), product portfolios, recent developments, future outlooks, strategic focus areas, and expert opinions.
? Examination of partnerships between industry stakeholders since 2017, considering partnership types, partners, company sizes, active players, and regional distributions in the antibiotics market.
? Exploration of completed and ongoing antibiotic-related clinical trials based on registration years, trial statuses, phases, patient populations, focus areas, sponsors, geographies, and active industry and non-industry players.
? Insightful analysis of key opinion leaders involved in antibiotic-related clinical trials, focusing on their qualifications, affiliations, geographic locations, target disease indications, prominence based on proprietary and third-party criteria.
? Elaboration on significant trends within the antibiotics industry, including drug pricing, outsourcing patterns, and the impact of COVID-19.
? An analysis of recently approved antibiotics based on parameters such as dosing, efficacy, competition, innovation, price, prevalence, administration route, activity spectrum, therapy type, and target bacteria.


Key Market Companies
? Bristol Myers Squibb
? Daiichi Sankyo
? GlaxoSmithKline
? Melinta Therapeutics
? Merck
? Pfizer